Price$79.43-46.58 (-36.97%)
2026-03-042026-06-05
News · 26 weeks118+29%
2025-12-142026-06-07
Mix4190d
- Insider25(61%)
- SEC Filings6(15%)
- Other5(12%)
- Earnings2(5%)
- Analyst2(5%)
- Dividends1(2%)
Latest news
25 items- PRZoetis Releases 2025 Sustainability Report: Advancing Sustainability in Animal Health for a Better FutureAchieved initial targets set in 2021 across Communities, Animals and Planet $35 million in grants disbursed by the Zoetis Foundation from 2021-2025 Received regulatory approvals for innovative vaccines and therapies, including science-driven solutions to address avian influenza in poultry and dairy cattle Reduced Scope 1 and 2 emissions by 29% since 2021, sourcing 85% of global electricity from renewable sources1 Zoetis published its 2025 Sustainability Report, highlighting progress achieved in 2025 through its Driven to Care strategy. This report marks a significant milestone as Zoetis delivers on its initial aspirations set in 2021 and introduces its next phase with renewed f
- SECSEC Form SD filed by Zoetis Inc.SD - Zoetis Inc. (0001555280) (Filer)
- ANALYSTZoetis downgraded by ArgusArgus downgraded Zoetis from Buy to Hold
- INSIDERDirector Stetter Mark converted options into 1,572 shares (SEC Form 4)4 - Zoetis Inc. (0001555280) (Issuer)
- SECZoetis Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders8-K - Zoetis Inc. (0001555280) (Filer)
- INSIDERDirector Parent Louise M converted options into 12,130 shares, increasing direct ownership by 75% to 28,394 units (SEC Form 4)4 - Zoetis Inc. (0001555280) (Issuer)
- PRZoetis to Participate in Upcoming Investor ConferencesZoetis Inc. (NYSE:ZTS) today announced that a representative of the company will participate in fireside chats at the following investor conferences. Stifel 2026 Jaws & Paws Conference on Thursday, May 28, 2026 at 3:00 p.m. ET William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026 at 1:20 p.m. CT Interested parties can access the live audio webcasts of the presentations by visiting https://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of each event. About Zoetis Zoetis is the world's leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing ca
- SECZoetis Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Zoetis Inc. (0001555280) (Filer)
- PRZoetis Declares Third Quarter 2026 DividendThe Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the third quarter of 2026. The dividend will be paid on Tuesday, September 1, 2026, to all holders of record of the Company's common stock as of the close of business on Monday, July 20, 2026. About Zoetis Zoetis is the world's leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertis
- INSIDERDirector Damelio Frank A bought $501,344 worth of shares (6,650 units at $75.39), increasing direct ownership by 45% to 21,458 units (SEC Form 4)4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERDirector Bisaro Paul bought $151,750 worth of shares (2,000 units at $75.88), increasing direct ownership by 8% to 27,862 units (SEC Form 4)4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERDirector Mccallister Michael B bought $233,273 worth of shares (3,000 units at $77.76) (SEC Form 4)4 - Zoetis Inc. (0001555280) (Issuer)
- SECSEC Form 10-Q filed by Zoetis Inc.10-Q - Zoetis Inc. (0001555280) (Filer)
- SECZoetis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Zoetis Inc. (0001555280) (Filer)
- PRZoetis Announces First Quarter 2026 ResultsRevenue of $2.3 Billion, Growing 3%, and Net Income of $601 Million, or $1.42 per Diluted Share, Flat and Increasing 6%, Respectively, on a Reported Basis Adjusted Net Income of $646 Million, or Adjusted Diluted EPS of $1.53 Flat Organic Operational Growth in Revenue and 1% Organic Operational Growth in Adjusted Net Income Revises Full Year 2026 Revenue Guidance to $9.680 - $9.960 Billion with Organic Operational Revenue Growth of 2% to 5% Revises Full Year 2026 Guidance for Organic Operational Growth in Adjusted Net Income to 2% to 6% Revises Guidance for Diluted EPS on an Adjusted Basis to $6.85 to $7.00 Zoetis Inc. (NYSE:ZTS), the world's leading animal health company,
- INSIDERExecutive Vice President Esch Kevin converted options into 259 shares and covered exercise/tax liability with 75 shares, increasing direct ownership by 47% to 578 units (SEC Form 4)4 - Zoetis Inc. (0001555280) (Issuer)
- ANALYSTCitigroup initiated coverage on Zoetis with a new price targetCitigroup initiated coverage of Zoetis with a rating of Buy and set a new price target of $145.00
- INSIDERSEC Form 4 filed by Fuller Julie4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Lagano Roxanne4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Ferran Astorga Jeannette4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Esch Kevin4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Driscoll Rimma4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Peck Kristin C4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Joseph Wetteny4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Sarbaugh Keith4 - Zoetis Inc. (0001555280) (Issuer)
ZTS FAQ
7 questionsWhat does Zoetis Inc. do?
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria...Where does ZTS stock trade?
Zoetis Inc. (ZTS) is listed on NYSE.What sector and industry is ZTS in?
Zoetis Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Zoetis Inc. go public?
Zoetis Inc. (ZTS) completed its IPO in 2013.What are analysts saying about ZTS?
Zoetis Inc. has had 8 recent analyst actions on file. The most recent action was from Argus: Hold on 2026-05-27.What companies are similar to ZTS?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ZTS side-by-side with any of them on Quantisnow.How can I track ZTS on Quantisnow?
Quantisnow aggregates Zoetis Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ZTS to receive live email and push alerts on every new disclosure.